Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL

To evaluate the efficacy and safety of Nanobody-Based CD19/CD22 Tandem Dual Chimeric Antigen Receptor (CAR) T-cell therapy in patients with relapsed or refractory B-ALL

Trial Details

NCT ID
NCT06880913
Phase
PHASE1 / PHASE2
Sponsor
Peking University People's Hospital
Status
RECRUITING
Cancer Type
Acute Lymphoblastic (ALL) Leukemia
Interventions
  • Nanobody-Based CD19/CD22 Tandem Dual CAR-T
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • The subject or their legally authorized representative (guardian) understands the study and voluntarily signs the informed consent form (ICF).
  • Male or female, aged 12 to 65 years at the time of signing the ICF (inclusive of the cutoff values).
  • Expected survival of at least 12 weeks. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 at the time of signing the ICF.
  • At the time of signing the ICF, the patient must be diagnosed with R/R B-ALL and meet the following criteria:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Acute Lymphoblastic (ALL) Leukemia Trials on Trialify →